Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2018

01-07-2018

Fixed-dose 4-factor prothrombin complex concentrate: we don’t know where we’re going if we don’t know how to get there

Authors: Scott T. Hall, Kyle C. Molina

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2018

Login to get access

Abstract

4-Factor Prothrombin Complex Concentrate (4F-PCC) is the standard-of-care intervention in patients with major bleeding taking oral vitamin K antagonists. Despite growing clinical experience with 4-FPCC, the optimal dosing strategy remains unclear. In balancing efficacy, safety, and cost of this treatment, many institutions have adopted a low, fixed-dose regimen, with average doses lower than that in the package insert. The fixed-dose 4F-PCC strategy is supported by the available observational studies and case reports; however, the current body of literature is highly heterogenous. The purpose of this narrative review is to address the advantages and shortcomings with clinical use of fixed-dose 4F-PCC, as well as limitations of the available literature. The heterogeneity of the current literature should guide future studies to support or refute this potentially life-saving intervention.
Literature
1.
go back to reference Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24(1):6–46. https://doi.org/10.1007/s12028-015-0222-x CrossRefPubMed Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24(1):6–46. https://​doi.​org/​10.​1007/​s12028-015-0222-x CrossRefPubMed
2.
go back to reference Kcentra (PC (2013) Concentrate (human)). CSL Behring, Marburg Kcentra (PC (2013) Concentrate (human)). CSL Behring, Marburg
3.
go back to reference Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(24):3042–3067. https://doi.org/10.1016/j.jacc.2017.09.1085 CrossRefPubMed Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(24):3042–3067. https://​doi.​org/​10.​1016/​j.​jacc.​2017.​09.​1085 CrossRefPubMed
4.
go back to reference Yasaka M, Sakata T, Minematsu K, Naritomi H (2002) Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 108(1):25–30CrossRefPubMed Yasaka M, Sakata T, Minematsu K, Naritomi H (2002) Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 108(1):25–30CrossRefPubMed
7.
go back to reference van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF (2006) Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118(3):313–320. https://doi.org/10.1016/j.thromres.2005.08.005 CrossRefPubMed van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF (2006) Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118(3):313–320. https://​doi.​org/​10.​1016/​j.​thromres.​2005.​08.​005 CrossRefPubMed
17.
go back to reference Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438. https://doi.org/10.1160/th11-01-0052 PubMedCrossRef Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438. https://​doi.​org/​10.​1160/​th11-01-0052 PubMedCrossRef
21.
22.
go back to reference Canadian Blood Services (2008) National advisory committee on blood and blood products: recommendations for use of Octaplex in Canada. Canadian Blood Services, Ottawa Canadian Blood Services (2008) National advisory committee on blood and blood products: recommendations for use of Octaplex in Canada. Canadian Blood Services, Ottawa
23.
go back to reference Canadian Blood Services (2011) National Advisory committee on blood and blood products: recommendations for use of Prothombin Complex Concentrates in Canada. Canadian Blood Services, Ottawa Canadian Blood Services (2011) National Advisory committee on blood and blood products: recommendations for use of Prothombin Complex Concentrates in Canada. Canadian Blood Services, Ottawa
24.
go back to reference Canadian Blood Services (2014) National Advisory committee on blood and blood products: recommendations for use of Prothombin Complex Concentrates in Canada. Canadian Blood Services, Ottawa Canadian Blood Services (2014) National Advisory committee on blood and blood products: recommendations for use of Prothombin Complex Concentrates in Canada. Canadian Blood Services, Ottawa
Metadata
Title
Fixed-dose 4-factor prothrombin complex concentrate: we don’t know where we’re going if we don’t know how to get there
Authors
Scott T. Hall
Kyle C. Molina
Publication date
01-07-2018
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1653-y

Other articles of this Issue 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.